Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-Aflibercept and Perfusion CT in Advanced Pancreatic Neuroendocrine Tumors
NCT02101918Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2014
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in Pancreatic neuroendocrine tumor (PanNET), sponsored by National Cancer Institute. Started Jun 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02101918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101918.